 BURLINGAME, Calif., May 05, 2021 GLOBE NEWSWIRE -- Corvus Pharmaceuticals, Inc. NASDAQ:CRVS, a clinical-stage biopharmaceutical company, today announced that it has completed the sale of approximately 10 million of its common shares pursuant to the Companys ATM program established on March 9, 2020 through Jefferies LLC Jefferies, acting as sales agent. 